# Open Label, Phase III Study of NABI-IGIV 10% [Immune Globulin Intravenous(Human), 10%] In Subjects With Primary Immune Deficiency Disorders (PIDD)

> **NCT00538915** · PHASE3 · COMPLETED · sponsor: **ADMA Biologics, Inc.** · enrollment: 63 (actual)

## Conditions studied

- Primary Immune Deficiency Disorders (PIDD)

## Interventions

- **BIOLOGICAL:** Nabi-IGIV 10% [Immune Globulin Intravenous (Human). 10%]

## Key facts

- **NCT ID:** NCT00538915
- **Lead sponsor:** ADMA Biologics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09
- **Primary completion:** 2009-07
- **Final completion:** 2009-07
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2021-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00538915

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00538915, "Open Label, Phase III Study of NABI-IGIV 10% [Immune Globulin Intravenous(Human), 10%] In Subjects With Primary Immune Deficiency Disorders (PIDD)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00538915. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*